Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study)

Lingyun Zhang(Gansu Agricultural University), Yunpeng Liu(Shenyang Institute of Automation), Bo Jin(Chengdu Medical College), Jin Xiuhua(Sheng Jing Hospital), Caijun Yuan(Sheng Jing Hospital), Ping Yu(First Hospital of China Medical University), Tao Sun(Wuhan University), Yu-zhi An, Jing Shi(Singapore Institute of Technology), Xiuna Zhang(Sheng Jing Hospital), Zhenghua Wang(Affiliated Hospital of Jining Medical University), Yuee Teng(First Hospital of China Medical University), Mingfang Zhao(First Hospital of China Medical University), Tiejun Chen(Center of Hubei Cooperative Innovation for Emissions Trading System), Xiaodong Xie(Jiangsu University), Zan Teng(First Hospital of China Medical University), Ying Chen(Nanjing Medical University), Jun Wang(Sheng Jing Hospital), Jian Zhang(University of Massachusetts Boston), Yuyang Dong(Sheng Jing Hospital), Ying Luo(Sheng Jing Hospital), Jingdong Zhang(Liaoning Cancer Hospital & Institute), Zhitu Zhu(Sheng Jing Hospital), Jinglei Qu(First Hospital of China Medical University), Man Li(Linyi People's Hospital), Jingyan Wang(Saint Luke's Hospital), Fugang Wen(Anshan Hospital), Lizhong Zhou(Sheng Jing Hospital), Feng Jin(Guiyang Medical University), Lingyu Fu(Heilongjiang University), Jing Liu(Fujian Medical University), Xiujuan Qu(First Hospital of China Medical University)
Journal of Clinical Oncology
August 30, 2017
10.1200/jco.2017.72.2538
Cited by 22

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508